Literature DB >> 19402064

Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.

Michael B Atkins1, Ronald M Bukowski, Bernard J Escudier, Robert A Figlin, Gary H Hudes, William G Kaelin, W Marston Linehan, David F McDermott, James W Mier, Ivan Pedrosa, Brian I Rini, Sabina Signoretti, Jeffrey A Sosman, Bin Tean Teh, Christopher G Wood, Amado J Zurita, Laura King.   

Abstract

The Third Cambridge Conference on Innovations and Challenges in Renal Cancer, a symposium held in Cambridge, Massachusetts, June 27-28, 2008, and chaired by Michael B. Atkins, was convened to discuss the current state of knowledge in the field, critique new data, stimulate communication among those involved in basic and clinical research, and offer recommendations for further study. Four main topics were discussed: genetics and molecular biology of renal cell cancer, staging and prognosis, systemic therapy, and correlative science and biomarkers in stage IV disease. The conference format combined brief presentations with extended periods of discussion. The conclusions and recommendations are summarized in this paper and presented in more detail in the individual papers that follow. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19402064      PMCID: PMC2892290          DOI: 10.1002/cncr.24229

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Brian I Rini; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; Jaime R Merchan; George Wilding; Michelle S Ginsberg; Jennifer Bacik; Sindy T Kim; Charles M Baum; M Dror Michaelson
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

Review 2.  Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics.

Authors:  W Marston Linehan; Peter A Pinto; Ramaprasad Srinivasan; Maria Merino; Peter Choyke; Lynda Choyke; Jonathan Coleman; Jorge Toro; Gladys Glenn; Cathy Vocke; Bert Zbar; Laura S Schmidt; Donald Bottaro; Len Neckers
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

Review 3.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

4.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma.

Authors:  E Sabo; A Boltenko; Y Sova; A Stein; S Kleinhaus; M B Resnick
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

6.  Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.

Authors:  Cedric de Bazelaire; David C Alsop; Daniel George; Ivan Pedrosa; Yongyu Wang; M Dror Michaelson; Neil M Rofsky
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

7.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

8.  Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen.

Authors:  Archana Bommi-Reddy; Ingrid Almeciga; Jacqueline Sawyer; Christoph Geisen; Wenliang Li; Ed Harlow; William G Kaelin; Dorre A Grueneberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-23       Impact factor: 11.205

9.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

Authors:  S A Rosenberg; J C Yang; D E White; S M Steinberg
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

10.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

View more
  9 in total

1.  Everolimus.

Authors:  Michael B Atkins; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-07       Impact factor: 84.694

Review 2.  Alterations in VHL as potential biomarkers in renal-cell carcinoma.

Authors:  Lucy Gossage; Tim Eisen
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

3.  Urinary biomarkers for the early diagnosis of kidney cancer.

Authors:  Jeremiah J Morrissey; Amy N London; Jingqin Luo; Evan D Kharasch
Journal:  Mayo Clin Proc       Date:  2010-04-07       Impact factor: 7.616

4.  Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

Authors:  David F McDermott; Charles G Drake; Mario Sznol; Toni K Choueiri; John D Powderly; David C Smith; Julie R Brahmer; Richard D Carvajal; Hans J Hammers; Igor Puzanov; F Stephen Hodi; Harriet M Kluger; Suzanne L Topalian; Drew M Pardoll; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Dan McDonald; Vindira Sankar; Jeffrey A Sosman; Michael B Atkins
Journal:  J Clin Oncol       Date:  2015-03-30       Impact factor: 44.544

5.  Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.

Authors:  Chen Xu; Agnes Lo; Anuradha Yammanuru; Aimee St Clair Tallarico; Kristen Brady; Akikazu Murakami; Natasha Barteneva; Quan Zhu; Wayne A Marasco
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

6.  Tumor necrosis on magnetic resonance imaging correlates with aggressive histology and disease progression in clear cell renal cell carcinoma.

Authors:  Peter Beddy; Elizabeth M Genega; Long Ngo; Nicole Hindman; Jesse Wei; Andrea Bullock; Rupal S Bhatt; Michael B Atkins; Ivan Pedrosa
Journal:  Clin Genitourin Cancer       Date:  2013-10-19       Impact factor: 2.872

7.  Interferon-gamma-induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells.

Authors:  David J Tate; John R Patterson; Cruz Velasco-Gonzalez; Emily N Carroll; Janie Trinh; Daniel Edwards; Ashok Aiyar; Beatriz Finkel-Jimenez; Arnold H Zea
Journal:  Int J Biol Sci       Date:  2012-09-06       Impact factor: 6.580

8.  The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma.

Authors:  Thai H Ho; Xian-De Liu; Yanqing Huang; Carla L Warneke; Marcella M Johnson; Anh Hoang; Pheroze Tamboli; Fen Wang; Eric Jonasch
Journal:  BMC Cancer       Date:  2015-04-18       Impact factor: 4.430

Review 9.  Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities.

Authors:  Angela Graves; Hannah Hessamodini; Germaine Wong; Wai H Lim
Journal:  Immunotargets Ther       Date:  2013-07-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.